High impact
AstraZeneca and Ionis Pharmaceuticals' gene silencer drug Wainua failed to reduce deaths in a heart condition trial, causing AstraZeneca's shares to fall.
bloomberg-industries07/09, 01:55 PM
Related assets
Coming up for AZN
Explore next
Latest AZN news
Jin1008/17, 07:48 PM
Jin1008/17, 01:48 PM
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.